We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of AGE on the Immune System (EAGESIS II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01959646
Recruitment Status : Completed
First Posted : October 10, 2013
Last Update Posted : February 26, 2016
Sponsor:
Information provided by (Responsible Party):
University of Florida

Brief Summary:
This is a nutritional intervention study using healthy overweight/obese humans to investigate if a supplement made from aged garlic extract has an impact on immunity. Following a baseline blood draw, participants will consume the capsules (garlic or placebo) for 42 days, at which time a second blood draw will occur. Tests for immune function and inflammation will be performed on both the baseline and 42 day samples. The investigators anticipate that the immune functions and biomarkers that are inflammatory in an overweight/obese population will be returning to normal after 42 days of consumption of this supplement. The investigators predict that AGE supplementation will benefit immunity and improve function while reducing inflammation in a stressed population (inflamed obese).

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: Aged Garlic Extract Supplementation Group Other: Standard for Groups Dietary Supplement: Placebo Not Applicable

Detailed Description:

Healthy, overweight adults age 25 to 65 will be recruited, consented and screened for eligibility. To assess for eligible study participants, the investigators will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually. To this end, universal precautions such as hand washing, glove change, new lancet, etc. will be utilized for every finger prick throughout the assessment.

Eligible participants will be enrolled, and subsequently return, to provide a baseline blood draw, and given their random group assignment. Participants will be asked to consume three (3) capsules of 600 mg AGE or placebo with food twice a day, for a total of 3.6 grams per day. This dose was determined from previous studies that analyzed for cardiovascular risk factors. The supplementation (AGE and placebo) intervention will occur over 42 days, sometime between September 2013 and February 2013. Blood will be taken again at 42 days, two (2) hours after subjects have taken their capsules. A light breakfast will be offered after both fasting blood draws.

Peripheral blood mononuclear cells will be isolated from the blood at both blood draws and either used fresh, or cultured in autologous serum for 24 hours. Freshly isolated cells will be used to determine compliance (glutathione); population numbers of γδ T cells and monocytes and their function (activation); and mRNA expression of IL-6 and TNF-α. After 24 hours of stimulation with a broad based mitogen, culture medium will be harvested and assayed for IL-6, and TNF-α proteins. The cultured cells will be assayed for γδ T cell and monocyte function and for mRNA analysis of IL-6 and TNF-α gene expression. The serum obtained at both blood draws will be used in cultures as autologous serum and for assay of inflammatory biomarkers (C-reactive protein, IL-6, TNF-α, adiponectin and leptin). Compliance will also be determined by capsule count.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 91 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: The Effect of Aged Garlic Extract Supplementation on the Immune System
Study Start Date : January 2014
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo Group
Other: Standard for Groups
To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.

Dietary Supplement: Placebo
Participants will be asked to consume three (3) placebo capsules with food twice a day.

Experimental: Aged Garlic Extract Supplementation
Aged Garlic Extract Supplementation Group
Dietary Supplement: Aged Garlic Extract Supplementation Group
Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
Other Name: AGE

Other: Standard for Groups
To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.




Primary Outcome Measures :
  1. Markers of immune health [ Time Frame: 6 weeks ]
    Number and function of gamma delta T-cells and monocytes


Secondary Outcome Measures :
  1. Markers of inflammation [ Time Frame: 6 weeks ]
    IL-6 and TNF alpha


Other Outcome Measures:
  1. Serum antioxidant status (compliance) [ Time Frame: 6 weeks ]
    Serum glutathione



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • ages 25-65
  • BMI > or = to 30 kg/m2
  • willing to discontinue dietary supplements
  • cRP between 2 and 10 mg/L

Exclusion Criteria:

  • medication for hypertension, high cholesterol, heart failure, angina, etc
  • diagnoses of diabetes, metabolic syndrome, arthritis, severe allergies, or any other compromised immune condition
  • blood pressure > 135/85 mmHg
  • serum triglycerides > 150 mg/dl
  • HDL cholesterol < 40 mg/dl for men or < 50 mg/dl for women
  • fasting glucose > 110 mg/dl

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01959646


Locations
Layout table for location information
United States, Florida
Food Science & Human Nutrition Building, University of Florida
Gainesville, Florida, United States, 32611
University of Florida
Gainesville, Florida, United States, 32611
Sponsors and Collaborators
University of Florida
Investigators
Layout table for investigator information
Principal Investigator: Susan Percival, PhD University of Florida
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT01959646    
Other Study ID Numbers: IRB201300529
First Posted: October 10, 2013    Key Record Dates
Last Update Posted: February 26, 2016
Last Verified: February 2016
Keywords provided by University of Florida:
Immune Function
Aged Garlic Extract
Supplementation
Inflammation